Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11706804PMC
http://dx.doi.org/10.1186/s40635-024-00702-yDOI Listing

Publication Analysis

Top Keywords

correction hello
4
hello protocol
4
protocol cluster
4
cluster randomized
4
randomized controlled
4
controlled trial
4
trial enhance
4
enhance interpersonal
4
interpersonal relationships
4
relationships team
4

Similar Publications

Ankylosing spondylitis (AS) is the historic term used for decades for the HLA-B27-associated inflammatory disease affecting mainly the sacroiliac joints (SIJ) and spine. Classification criteria for AS have radiographic sacroiliitis as a dominant characteristic. However, with the availability of MRI of SIJ, it could be demonstrated that the disease starts long before definite SIJ changes become visible on radiographs.

View Article and Find Full Text PDF

Measurement of Aniseikonia Tolerance in Binocular Fusion.

Optom Vis Sci

May 2023

Department of Ophthalmology, School of Medicine, Kitasato University, Sagamihara, Japan.

Significance: The determination of aniseikonia tolerance may aid in developing optimal treatment plans for cataract surgery, refractive surgery, and refractive correction with glasses and contact lenses.

Purpose: This study aimed to measure aniseikonia tolerance.

Methods: We included 33 patients (mean age ± standard deviation, 28.

View Article and Find Full Text PDF

Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis.

JAMA Netw Open

November 2022

National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP) Centre, Université Paris Cité, Paris, France.

Importance: Results of randomized clinical trials have demonstrated rituximab's noninferiority to cyclophosphamide as induction therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV), with neither treatment having a specific advantage for granulomatosis with polyangiitis (GPA). However, post hoc analysis results have suggested that rituximab might be more effective than cyclophosphamide in inducing remission in patients with proteinase 3-positive AAV.

Objective: To compare the effectiveness of rituximab and cyclophosphamide in inducing GPA remission in a large population of unselected patients.

View Article and Find Full Text PDF